Physician profile
Barbara Baggstrom
NPI 1104894989
$3,290.06
in general payments reported to CMS, 2019-2025
25 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $801 · 2022: $729 · 2023: $636 · 2024: $843 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $450.96 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Supernus Pharmaceuticals, INC. | $342.67 | 2021-2025 | Qelbree |
| Kaleo, INC. | $277.58 | 2021-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $236.69 | 2021-2025 | Gardasil 9, Vaxelis, Gardasil |
| Neos Therapeutics, LP | $233.55 | 2021-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Corium, LLC | $231.89 | 2022-2024 | Azstarys, Azstarys |
| Pfizer INC. | $185.06 | 2021-2024 | |
| Tris Pharma INC | $176.94 | 2021-2025 | Dyanavel Xr |
| Abbvie INC. | $168.07 | 2021-2022 | |
| Sanofi Pasteur INC. | $137.14 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $130.86 | 2023-2024 | Jornay Pm |
| Cumberland Pharmaceuticals, INC. | $127.51 | 2023-2024 | Kristalose |
| Tempus Ai, INC | $126.65 | 2024 | |
| Aytu Biopharma, INC. | $84.39 | 2021-2024 | |
| Cranial Technologies, INC | $59.81 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $59.17 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $57.50 | 2021-2022 | |
| Seqirus USA INC | $52.61 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Collegium Pharmaceutical, INC. | $47.89 | 2025 | Jornay Pm |
| Genzyme Corporation | $19.94 | 2023 | |
| Botanix Sb INC | $18.28 | 2025 | Sofdra |
| Exeltis, USA INC. | $17.90 | 2024 | Slynd |
| Astrazeneca Pharmaceuticals LP | $16.48 | 2024 | Flumist Quadrivalent |
| Alk-Abello, INC | $15.42 | 2025 | Odactra, Ragwitek, Grastek |
| Nestle Healthcare Nutrition INC. | $15.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Baggstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.